Chemical Peels For Acne Treatment

Spear Dermatology Products, Inc. announces Refissa a new formulation of Tretinoin, approved by the U.S. Food and Drug Administration (FDA). Refissa is the only 0.05% prescription strength, fragrance-free, emollient-based Tretinoin Cream. This topical Tretinoin cream helps to reduce fine facial wrinkles, rough skin, and irregular pigmentation. Refissa’s emollient formulation is for patients with normal to dry skin, who should also protect their skin from the sun by wearing a daily sunscreen.

Most dermatologists view topical retinoids as the cornerstone of treatment for sun damaged skin and acne.1 Most retinoids, however, are formulated and indicated exclusively for the acne treatment. Among topical retinoids, Tretinoin is the “Gold Standard” of treatments, and Refissa, formulated in a moisturizing base, is an ideal option for mature patients with drier photo damaged skin.

With the launch of Refissa, Spear Dermatology Products, Inc. is well-poised to be at the forefront of the booming prescription topical facial rejuvenation market. Total sales for this market exceeded $394m in 2002 and increased to more than $494m in 2007. It is expected that market sales will surpass $513m by 2012. Refissa stands out from all other facial rejuvenation products as it’s the only 0.05% strength prescription Tretinoin cream on the market that is both fragrance-free and contains a moisturizing, emollient base that is proven to be clinically safe and effective.

Refissa has gone through the extensive testing required to earn FDA approval and offers patients a safe, cost-effective prescription alternative to expensive cosmetic surgery or procedures. A 40 gram tube of Refissa may last 2-3 months, depending on individual usage patterns and costs on average, less than $2.00 per day. Refissa will be available for distribution during the first week of June, 2009.